Atherosclerosis. Macrophages. Viral infections

Atherosclerosis. Macrophages. Viral infections

Автор: Ryabov V.V., Alekseeva Ya. V., Gombozhapova A.E., Sokolova Ya. V., Karpov R.S.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 2 т.36, 2021 года.

Бесплатный доступ

The emergence of new COVID-19 infection aggravated the existing issues and gave rise to new challenges associated with the impact of viruses on the atherosclerotic process and development of cardiovascular complications. Atherosclerosis is a multifactorial disease and its progression is largely determined by dyslipidemia and chronic low-grade systemic vascular inflammation. There are a number of viruses known to be involved in maintaining the inflammatory state through the prolonged viral persistence and replication in the macrophages whose plasticity changes due to the infection. The viruses can trigger the pro-atherogenic cytokine response through the diverse macrophage-dependent mechanisms. There is lack of data regarding impact of viral infections on the monocyte/macrophage plasticity and possible control of inflammation in atherogenesis. It is still unclear whether the relationships between the viral diseases and atherosclerosis are causal or merely associative. In this review, we summarize and critically analyze the current state of knowledge regarding the virus-related mechanisms promoting atherosclerosis.

Еще

Atherosclerosis, viral infections, inflammation, macrophages, latent viral infection, atherosclerosis complications

Короткий адрес: https://sciup.org/149136648

IDR: 149136648   |   DOI: 10.29001/2073-8552-2021-36-2-14-22

Список литературы Atherosclerosis. Macrophages. Viral infections

  • Frangogiannis N.G. The immune system and the remodeling in-farcted heart: cell biological insights and therapeutic opportunities. J. Cardiovasc. Pharmacol. 2014;63(3):185-195. DOI: 10.1097/ FJC.0000000000000003.
  • Chistiakov D.A., Bobryshev Y.V., Orekhov A.N. Changes in transcriptome of macrophages in atherosclerosis. J. Cell. Mol. Med. 2015;19(6):1163-1173. DOI: 10.1111/jcmm.12591.
  • Medbury H.J., Williams H., Fletcher J.P. Clinical significance of macrophage phenotypes in cardiovascular disease. Clinical and Translational Medicine. 2014;3(1):e63. DOI: 10.1186/s40169-014-0042-1.
  • Colin S., Chinetti-Gbaguidi G., Staels B. Macrophage phenotypes in atherosclerosis. Immunological Reviews. 2014;262(1):153-166. DOI: 10.1111/imr.12218.
  • Ballesteros-Ortega D., Martínez-González O., Gómez-Casero R.B., Quintana-Díaz M., de Miguel-Balsa E., Martín-Parra C. et al. Characteristics of patients with myocardial infarction with nonobstructive coronary arteries (MINOCA) from the ARIAM-SEMICYUC registry: development of a score for predicting MINOCA. Vasc. Health Risk Manag. 2019;13:57-67. DOI: 10.2147/VHRM.S185082.
  • Zhang L., Wang C.C. Inflammatory response of macrophages in infection. Hepatobiliary Pancreat. Dis. Int. 2014;13(2):138-152. DOI: 10.1016/S1499-3872(14)60024-2.
  • Quillard T., Franck G., Mawson T., Folco E., Libby P. Mechanisms of Erosion of Atherosclerotic Plaques. Curr. Opin. Lipidol. 2017;28(5):434-441. DOI: 10.1097/MOL.0000000000000440.
  • Karpov R.S., Dudko V.A. Atherosclerosis: pathogenesis, health clinic, functional diagnostics, treatment. Tomsk: STT; 1998:672 (In Russ.).
  • Falk E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006;47(8):7-12. DOI: 10.1016/j.jacc.2005.09.068.
  • Aronov D.M., Lupanov V.P. Some aspects of the pathogenesis of atherosclerosis. The Journal of Atherosclerosis and Dyslipidemias. 2011;1:48-56 (In Russ.).
  • Wong N.D., Levy D. Legacy of the Framingham heart study: Rationale, design, initial findings, and implications. Glob. Heart. 2013;8(1):3-9. DOI: 10.1016/j.gheart.2012.12.001.
  • Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F. et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur. Heart J. 2010;31(23):2844-2853. DOI: 10.1093/eurheartj/ ehq386.
  • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383-1389. DOI: 10.1016/S0140-6736(94)90566-5.
  • Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. DOI: 10.1001/jama.295.13.jpc60002.
  • Chaudhary R., Garg J., Shah N., Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J. Cardiol. 2017;9(2):76-91. DOI: 10.4330/wjc.v9.i2.76.
  • Catapano A.L., Graham I., Backer G.D., Wiklund O., Chapman M.J., Drexel H. et al. 2016 ESC/EAS Guidelines for the Management of Dys-lipidaemias. Eur. Heart J. 2016;37(39): 2999-3058. DOI: 10.1093/eu-rheartj/ehw272.
  • Jenson H.B. Viral infections of humans. Epidemiology and control; 3rd ed. Yale J. Biol. Med. 1990;63(1):65-66.
  • Hansson G.K. Immune mechanisms in atherosclerosis. Arterio-scler. Thromb. Vasc. Biol. 2001;21(12):1876-1890. DOI: 10.1161/ hq1201.100220.
  • Shah P., Bajaj S., Virk H., Bikkina M., Shamoon F. Rapid Progression of Coronary Atherosclerosis: A Review. Thrombosis. 2015;634938:6. DOI: 10.1155/2015/634983.
  • Galkina E., Ley K. I mmune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol. 2009;27:165-197. DOI: 10.1146/annurev.im-munol.021908.132620.
  • Rogacev K.S., Cremers B., Zawada A.M., Seiler S., Binder N., Ege P. et al. CD14, CD16 monocytes independently predict cardiovascular events: A cohort study of 951 patients referred for elective coronary angiography. J. Am. Coll. Cardiol. 2012;60(16):1512-1520. DOI: 10.1016/j. jacc.2012.07.019.
  • Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604. DOI: 10.1016/j. immuni.2010.05.007.
  • Gombozhapova A.E., Rogovskaya Yu.V., Rebenkova M.S., Kzhysh-kovskaya Yu.G., Ryabov V.V. CD68 and STABILIN-1 positive macrophages in postinfarction myocardial regeneration. Russian Journal of Cardiology. 2017;151(11):56-61 (In Russ.). DOI: 10.15829/1560-40712017-11-56-61.
  • Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11(11):723-737. DOI: 10.1038/ nri3073.
  • Moore K., Sheedy F., Fisher E. Macrophages in atherosclerosis: A dynamic balance. Nat. Rev. Immunol. 2013;(13):709-721. DOI: 10.1038/ nri3520.
  • Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C. et al. Antiinflammatory therapy with ganakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377(12):1119-1131. DOI: 10.1056/NEJMoa1707914.
  • Nikitina E., Larionova I., Choinzonov E., Kzhyshkowska J. Monocytes and macrophages as viral targets and reservoirs. Int. J. Mol. Sci. 2018;19(9):2821. DOI: 10.3390/ijms19092821.
  • Okabe Y., Medzhitov R. Tissue biology perspective on macrophages. Nat. Immunol. 2016;(17):9-17. DOI: 10.1038/ni.3320.
  • Gordon S., Plüddemann A., Martinez Estrada F. Macrophage heterogeneity in tissues: Phenotypic diversity and functions. Immunol. Rev. 2014;262(1):36-55. DOI: 10.1111/imr.12223.
  • Campbella L.A., Rosenfeld M.E. Infection and atherosclerosis development. Arch. Med. Res. 2015;46(5):269-284. DOI: 10.1016/j.arc-med.2015.05.006.
  • Ellis R.W. Infection and coronary heart disease. J. Med. Microbiol. 1997;46(7):535-539. DOI: 10.1099/00222615-46-7-535.
  • Lawson J.S. Multiple infectious agents and the origins of atherosclerotic coronary artery disease. Front. Cardiovasc. Med. 2016;3:30. DOI: 10.3389/fcvm.2016.00030.
  • Rezaee-Zavareh M.S., Tohidi M., Sabouri A., Ramezani-Binabaj M., Sa-deghi-Ghahrodi M., Einollahi B. Infectious and coronary artery disease. ARYA Atheroscler. 2016;12(1):41-49.
  • Jha H.C., Mittal A. Impact of viral and bacterial infections in coronary artery disease patients. World J. Transl. Med. 2013;2(3):49-55. DOI: 10.5528/wjtm.v2.i3.49.
  • Dahala U., Sharmab D., Dahalc K. An Unsettled Debate about the Potential Role of Infection in Pathogenesis of Atherosclerosis. J. Clin. Med. Res. 2017;9(7):547554. DOI: 10.14740/jocmr3032w.
  • Siscovick D.S., Schwartz S.M., Corey L., Grayston T., Ashley R., Wang S. et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study. Circulation. 2000;102(19):2335-2340. DOI: 10.1161/01.cir.102.19.2335.
  • Lawson J.S., Glenn W.K., Tran D.D., Ngan C.C., Duflou J.A., Whitaker N.J. Identification of human papilloma viruses in atheromatous coronary artery disease. Front. Cardiovasc. Med. 2015;(2):17. DOI: 10.3389/ fcvm.2015.00017.
  • Minassian C., Thomas S.L., Smeeth L., Douglas I., Brauer R., Langan S.M. Acute Cardiovascular Events after Herpes Zoster: A Self-Controlled Case Series Analysis in Vaccinated and Unvaccinated Older Residents of the United States. PLoS Med. 2015;12(12):e1001919. DOI: 10.1371/ journal.pmed.1001919.
  • Nikitskaya E.A., Maryukhnich E.V., Savvinova P.P., Pinegina N.V., Shpektor A.V., Vasilieva E.Yu. et al. Human herpesviruses and atherosclerosis. Modern point of view. Creative Cardiology. 2015;(2):54-62 (In Russ.). DOI: 10.15275/kreatkard.2015.02.05.
  • Shi Y., Tokunaga O. Herpesvirus (HSV-1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue. Pathol. Int. 2002;52(1):31-39. DOI: 10.1046/j.1440-1827.2002.01312.
  • O'Connor S., Taylor C., Campbell L.A., Epstein S., Libby P. Potential infectious etiologies of atherosclerosis: A multifactorial perspective. Emerg. Infec. Dis. 2001;7(5):780-788. DOI: 10.3201/eid0705.010503.
  • Jenkins F.J., Hoffman L.J. Overview of herpesviruses. Infectious Causes of Cancer: Targets for Intervention. 2000;33-49. DOI: 10.1385/1-59259024-1:33.
  • Shestakova I.V., Malyshev N.V., Lebedev V.V. Herpes simplex in adults: Guidelines. Moscow; 2014:129 (In Russ.).
  • Fabricant C.G., Fabricant J., Minick C.R., Litrenta M.M. Herpesvirus-in-duced atherosclerosis in chickens. Fed. Pro. 1983;42(8): 2476-2479.
  • Wu P.Y., Sun D.D., Wang Y., Liu W., Yang J. Herpes simplex virus type 1 and type 2 infection increases atherosclerosis risk: Evidence based on a meta-analysis. Biomed Res. Int. 2016;2016:2640865. DOI: 10.1155/2016/2630865.
  • Hsu H., Nicholson A.C., Pomerantz K.B., Kaner R.J., Hajja D.P. Altered cholesterol erafficking in herpesvirus-infected arterial cells. Evidence for viral protein kinase-mediated cholesterol accumulation. J. Biol. Chem. 1995;270(33):19630-19637.
  • Romeo M.A., Santarelli R., Gilardini Montani M.S., Gonnella R., Be-nedetti R. Faggioni A. et al. Viral wnfection and autophagy dysregula-tion: The case of HHV-6, EBV and KSHV. Cells. 2020;9(12):2624. DOI: 10.3390/cells9122624.
  • Young L.S., Rickinson A.B. Epstein-Barr virus: 40 Years on. Nat. Rev. Cancer. 2004;4(10):757-768. DOI: 10.1038/nrc1452.
  • Goreyko T.V., Kalinina N.M., Drygina L.B. The modern conceptions about immunopathogenesis of the infection caused by the Epstein-Barr virus. Infec. Immun. 2011;1(2):121-130 (In Russ.).
  • Abbas W., Tariq M., Iqbal M., Kumar A., Herbein G. Eradication of HIV-1 from the macrophage reservoir: an uncertain goal? Viruses. 2015;7(4):1578-1598. DOI: 10.3390/v7041578.
  • Gazi I.F., Elisaf M.S. Effect of infection on lipid profile: Focus on Epstein-Barr virus. Clin. Lipidol. 2010;5(5):607-610. DOI: 10.2217/ clp.10.53.
  • Sorlie P.D., Adam E., Melnick S.L., Folsom A., Skelton T., Chamb-less L.E. et al. Cytomegalovirus/herpesvirus and carotid atherosclerosis: The aric study. J. Med. Virol. 1994;42(1):33-37. DOI: 10.1002/ jmv.1890420107.
  • Koon-Chu Y., Abdul-Aleem M., Costa H., Taher C., Badrnya S., Assinger A. et al. Human cytomegalovirus up-regulates endothelin receptor type B: Implication for vasculopathies? Open Forum Infect. Dis. 2015;2(4):ofv155. DOI: 10.1093/ofid/ofv155.
  • Rabczynski M., Fiodorenko-Dumas Z., Mastej K., Dumas I., Adamiec R., Paprocka-Borowicz M. A relationship between serological markers of chronic C. pneumoniae and CMV infection and hsp60 in patients with atherosclerotic carotid stenosis. Acta Biochimica Polonica. 2015;62(1):89-95.
  • Zanone M.M., Favaro E., Conaldi P.G., Greening J., Bottelli A., Perin P.C. et al. Persistent infection of human microvascular endothelial cells by Coxsackie B viruses induces increased expression of adhesion molecules. J. Immunol. 2003;171(1):438-446. DOI: 10.4049/jimmu-nol.171.1.438.
  • Gholoobi A., Meshkat Z., Baghani A., Alavi M.S., Mohammadpoor T., Momen-Heravi M. et al. Comparison of the prevalence of enteroviruses in blood samples of patients with and without unstable angina. ARYA Atherosclerosis. 2017;13(4):161-166.
  • Andreoletti L., Venteo L., Douche-Aourik F., Canas F., de la Grand-maison L.G., Jacques J. Active Coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction. J. Am. Coll. Card. 2007;50(23):2207-2214. DOI: 10.1016/j.jacc.2007.07.080.
  • Mohamadpoor T., Nabavinia M.S., Gholoobi A., Alavi M.S., Meshkat Z. Enteroviruses in acute myocardial infarction. Iran J. Public. Health. 2012;41(8):71-74.
  • Freiberg M.S., Chang C.C.H., Kuller L.H., Skanderson M., Lowy E., Kraemer K.L. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 2013;173(8):614-622. DOI: 10.1001/jamainternmed.2013.3728.
  • Kirichenko T.V., Myasoedova V.A., Shimonova T.E., Melnichenko A.A., Sviridov D., Sobenin I.A. et al. Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Biosci. Rep. 2018;38(4):BSR20180597. DOI: 10.1042/BSR20180597.
  • Barnes M., Heywood A.E., Mahimbo A., Rahman B., Newall A.T., Mac-intyre C.R. Acute myocardial infarction and influenza: A meta-analysis of case-control studies. Heart. 2015;101(21):1738-1747. DOI: 10.1136/ heartjnl-2015-307691.
Еще
Статья научная
SciUp 2024 © 2024 ©